Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE I: Ublituximab in Relapsing Multiple Sclerosis
NCT03277261Phase 3Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2017
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc.. Started Sep 2017; status: completed.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03277261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277261.